{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T22:24:03Z","timestamp":1757543043268,"version":"3.37.3"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:00:00Z","timestamp":1724716800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Italian Association for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021856","name":"Ministero dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.leukres.2024.107568","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T02:23:34Z","timestamp":1724379814000},"page":"107568","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Evolution of transcriptomic profiles in relapsed inv(16) acute myeloid leukemia"],"prefix":"10.1016","volume":"145","author":[{"given":"Serena","family":"Travaglini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgia","family":"Silvestrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Attardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Fanciulli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Scalera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Antonelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Maurillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaele","family":"Palmieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariadomenica","family":"Divona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludovica","family":"Ciuffreda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arianna","family":"Savi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovangiacinto","family":"Paterno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiziana","family":"Ottone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina","family":"Barbieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaroslaw P.","family":"Maciejewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmelo","family":"Gurnari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gennaro","family":"Ciliberto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Teresa","family":"Voso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.leukres.2024.107568_bib1","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s41408-021-00503-6","article-title":"Core binding factor acute myelogenous leukemia-2021 treatment algorithm","volume":"11","author":"Borthakur","year":"2021","journal-title":"Blood Cancer J."},{"issue":"24","key":"10.1016\/j.leukres.2024.107568_bib2","doi-asserted-by":"crossref","first-page":"5705","DOI":"10.1200\/JCO.2005.15.610","article-title":"Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study","volume":"23","author":"Marcucci","year":"2005","journal-title":"J. Clin. Oncol. J. Am. Soc. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.leukres.2024.107568_bib3","first-page":"84","article-title":"Comprehensive mutation profile in acute myeloid leukemia patients with RUNX1-RUNX1T1 or CBFB-MYH11 fusions","volume":"39","author":"Qin","year":"2022","journal-title":"Turk. J. Haematol. J. Turk. Soc. Haematol."},{"issue":"12","key":"10.1016\/j.leukres.2024.107568_bib4","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/ajh.23821","article-title":"Core-binding factor acute myeloid leukemia: heterogeneity, monitoring, and therapy","volume":"89","author":"Solh","year":"2014","journal-title":"Am. J. Hematol."},{"issue":"12","key":"10.1016\/j.leukres.2024.107568_bib5","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1182\/blood-2012-10-462879","article-title":"Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia","volume":"121","author":"Jourdan","year":"2013","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.leukres.2024.107568_bib6","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nrc840","article-title":"Core-binding factors in haematopoiesis and leukaemia","volume":"2","author":"Speck","year":"2002","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.leukres.2024.107568_bib7","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.molcel.2020.12.005","article-title":"Definition of a small core transcriptional circuit regulated by AML1-ETO","volume":"81","author":"Stengel","year":"2021","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.leukres.2024.107568_bib8","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0959-437X(02)00018-7","article-title":"The core-binding factor leukemias: lessons learned from murine models","volume":"13","author":"Downing","year":"2003","journal-title":"Curr. Opin. Genet Dev."},{"issue":"2","key":"10.1016\/j.leukres.2024.107568_bib9","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2141.2006.06276.x","article-title":"The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations","volume":"135","author":"Appelbaum","year":"2006","journal-title":"Br. J. Haematol."},{"issue":"18","key":"10.1016\/j.leukres.2024.107568_bib10","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1200\/JCO.2004.03.012","article-title":"Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup","volume":"22","author":"Schlenk","year":"2004","journal-title":"J. Clin. Oncol. J. Am. Soc. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.leukres.2024.107568_bib11","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/00062752-200107000-00004","article-title":"Function of the inv(16) fusion gene CBFB-MYH11","volume":"8","author":"Kundu","year":"2001","journal-title":"Curr. Opin. Hematol."},{"issue":"2","key":"10.1016\/j.leukres.2024.107568_bib12","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1182\/blood-2002-11-3527","article-title":"Prognosis of inv(16)\/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup","volume":"102","author":"Delaunay","year":"2003","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2024.107568_bib13","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1200\/JCO.1993.11.4.690","article-title":"Granulocytic sarcoma is associated with the 8;21 translocation in acute myeloid leukemia","volume":"11","author":"Tallman","year":"1993","journal-title":"J. Clin. Oncol. J. Am. Soc. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.leukres.2024.107568_bib14","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1038\/ng.3709","article-title":"The genomic landscape of core-binding factor acute myeloid leukemias","volume":"48","author":"Faber","year":"2016","journal-title":"Nat. Genet"},{"issue":"10","key":"10.1016\/j.leukres.2024.107568_bib15","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1182\/blood-2018-05-852822","article-title":"Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients","volume":"133","author":"Christen","year":"2019","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.leukres.2024.107568_bib16","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/blood-2015-12-688705","article-title":"Comprehensive mutational profiling of core binding factor acute myeloid leukemia","volume":"127","author":"Duployez","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2024.107568_bib17","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/leu.2015.141","article-title":"Somatic mutational landscape of AML with inv(16) or t(8;21) identifies patterns of clonal evolution in relapse leukemia","volume":"30","author":"Sood","year":"2016","journal-title":"Leukemia"},{"issue":"24","key":"10.1016\/j.leukres.2024.107568_bib18","doi-asserted-by":"crossref","first-page":"6342","DOI":"10.1182\/bloodadvances.2020002673","article-title":"Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication","volume":"4","author":"Jahn","year":"2020","journal-title":"Blood Adv."},{"issue":"8","key":"10.1016\/j.leukres.2024.107568_bib19","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1158\/0008-5472.CAN-15-1015","article-title":"Genomic profiling of pediatric acute myeloid leukemia reveals a changing mutational landscape from disease diagnosis to relapse","volume":"76","author":"Farrar","year":"2016","journal-title":"Cancer Res"},{"issue":"23","key":"10.1016\/j.leukres.2024.107568_bib20","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1182\/blood.V126.23.802.802","article-title":"Mutational and transcriptomic landscape of AML with core-binding factor rearrangements","volume":"126","author":"Lavall\u00e9e","year":"2015","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.leukres.2024.107568_bib21","doi-asserted-by":"crossref","first-page":"5122","DOI":"10.1182\/bloodadvances.2023010173","article-title":"Applicability of 2022 classifications of acute myeloid leukemia in the real-world setting","volume":"7","author":"Attardi","year":"2023","journal-title":"Blood Adv."},{"issue":"19","key":"10.1016\/j.leukres.2024.107568_bib22","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1182\/blood.2020010603","article-title":"Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia","volume":"138","author":"Awada","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107568_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.828072","article-title":"Diagnostic workup of acute myeloid leukemia: what is really necessary? An Italian survey","volume":"12","author":"Voso","year":"2022","journal-title":"Front Oncol."},{"issue":"12","key":"10.1016\/j.leukres.2024.107568_bib24","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2024.107568_bib25","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management ofAML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107568_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-023-02054-0","article-title":"Expression profiling of extramedullary acute myeloid leukemia suggests involvement of epithelial-mesenchymal transition pathways","author":"Ottone","year":"2023","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.leukres.2024.107568_bib27","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1744-7348.1939.tb06990.x","article-title":"The toxicity of poisons applied jointly1","volume":"26","author":"BLISS","year":"1939","journal-title":"Ann. Appl. Biol."},{"issue":"2","key":"10.1016\/j.leukres.2024.107568_bib28","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1080\/19466315.2018.1437071","article-title":"Evaluation of drug combination effect using a Bliss independence dose-response surface model","volume":"10","author":"Liu","year":"2018","journal-title":"Stat. Biopharm. Res"},{"issue":"1","key":"10.1016\/j.leukres.2024.107568_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2022.113112","article-title":"IL-6 promotes chemoresistance via upregulating CD36 mediated fatty acids uptake in acute myeloid leukemia","volume":"415","author":"Zhang","year":"2022","journal-title":"Exp. Cell Res"},{"issue":"8","key":"10.1016\/j.leukres.2024.107568_bib30","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1038\/s41375-023-01946-5","article-title":"MCL1 regulates AML cells metabolism via direct interaction with HK2. Metabolic signature at onset predicts overall survival in AMLs\u2019 patients.","volume":"37","author":"Catalano","year":"2023","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.leukres.2024.107568_bib31","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.13076","article-title":"Role of CXCR4 in the progression and therapy of acute leukaemia","volume":"54","author":"Su","year":"2021","journal-title":"Cell Prolif."},{"issue":"1","key":"10.1016\/j.leukres.2024.107568_bib32","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12967-017-1287-4","article-title":"PIM-1 mRNA expression is a potential prognostic biomarker in acute myeloid leukemia","volume":"15","author":"Cheng","year":"2017","journal-title":"J. Transl. Med"},{"issue":"2","key":"10.1016\/j.leukres.2024.107568_bib33","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s12253-018-0476-7","article-title":"BCL3 expression is a potential prognostic and predictive biomarker in acute myeloid leukemia of FAB subtype M2","volume":"25","author":"Niu","year":"2019","journal-title":"Pathol. Oncol. Res"},{"issue":"4","key":"10.1016\/j.leukres.2024.107568_bib34","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s10555-018-9772-7","article-title":"Roles of the mitochondrial genetics in cancer metastasis: not to be ignored any longer","volume":"37","author":"Beadnell","year":"2018","journal-title":"Cancer Metastas-.-. Rev."},{"issue":"40","key":"10.1016\/j.leukres.2024.107568_bib35","doi-asserted-by":"crossref","first-page":"67117","DOI":"10.18632\/oncotarget.19962","article-title":"Mitochondrial biomarkers predict tumor progression and poor overall survival in gastric cancers: Companion diagnostics for personalized medicine","volume":"8","author":"Sotgia","year":"2017","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.leukres.2024.107568_bib36","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.leukres.2010.01.009","article-title":"Granulocytic sarcoma of abdomen in acute myeloid leukemia patient with inv(16) and t(6;17) abnormal chromosome: case report and review of literature","volume":"34","author":"Zhang","year":"2010","journal-title":"Leuk. Res"},{"issue":"11","key":"10.1016\/j.leukres.2024.107568_bib37","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1158\/1078-0432.CCR-17-3070","article-title":"Oxidative phosphorylation as an emerging target in cancer therapy","volume":"24","author":"Ashton","year":"2018","journal-title":"Clin. Cancer Res"},{"issue":"1","key":"10.1016\/j.leukres.2024.107568_bib38","doi-asserted-by":"crossref","first-page":"13041","DOI":"10.1038\/ncomms13041","article-title":"Tissue-specific and convergent metabolic transformation of cancer correlates with metastatic potential and patient survival","volume":"7","author":"Gaude","year":"2016","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.leukres.2024.107568_bib39","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/ars.2012.4883","article-title":"Mitochondria-mediated energy adaption in cancer: the H(+)-ATP synthase-geared switch of metabolism in human tumors","volume":"19","author":"S\u00e1nchez-Arag\u00f3","year":"2013","journal-title":"Antioxid. Redox Signal"},{"issue":"5930","key":"10.1016\/j.leukres.2024.107568_bib40","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.1160809","article-title":"Understanding the Warburg effect: the metabolic requirements of cell proliferation","volume":"324","author":"Vander Heiden","year":"2009","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.leukres.2024.107568_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/cells8090967","article-title":"Targeting metabolic reprogramming in acute myeloid leukemia","volume":"8","author":"Castro","year":"2019","journal-title":"Cells"},{"issue":"10","key":"10.1016\/j.leukres.2024.107568_bib42","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1182\/blood.2022018092","article-title":"Metabolism in acute myeloid leukemia: mechanistic insights and therapeutic targets","volume":"141","author":"Mishra","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2024.107568_bib43","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41408-023-00928-1","article-title":"Efficacy of venetoclax combined with hypomethylating agents in young, and unfit patients with newly diagnosed core binding factor acute myeloid leukemia","volume":"13","author":"Zhang","year":"2023","journal-title":"Blood Cancer J."},{"issue":"2","key":"10.1016\/j.leukres.2024.107568_bib44","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","article-title":"Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study","volume":"19","author":"DiNardo","year":"2018","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.leukres.2024.107568_bib45","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","article-title":"Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in acute myeloid leukemia patients","volume":"24","author":"Pollyea","year":"2018","journal-title":"Nat. Med"},{"issue":"3","key":"10.1016\/j.leukres.2024.107568_bib46","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.stem.2012.12.013","article-title":"BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells","volume":"12","author":"Lagadinou","year":"2013","journal-title":"Cell Stem Cell"},{"issue":"1","key":"10.1016\/j.leukres.2024.107568_bib47","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-15051-z","article-title":"Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma","volume":"11","author":"Bajpai","year":"2020","journal-title":"Nat. Commun."},{"issue":"Supplement 1","key":"10.1016\/j.leukres.2024.107568_bib48","doi-asserted-by":"crossref","first-page":"5959","DOI":"10.1182\/blood-2022-162513","article-title":"Electron transport chain complex v inhibition enhances the antileukemic activity of low-dose venetoclax in acute myeloid leukemia","volume":"140","author":"Ramsey","year":"2022","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.leukres.2024.107568_bib49","doi-asserted-by":"crossref","first-page":"7481","DOI":"10.1074\/jbc.RA120.013366","article-title":"IACS-010759, a potent inhibitor of glycolysis-deficient hypoxic tumor cells, inhibits mitochondrial respiratory complex I through a unique mechanism","volume":"295","author":"Tsuji","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.leukres.2024.107568_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215582","article-title":"Metformin sensitizes AML cells to chemotherapy through blocking mitochondrial transfer from stromal cells to AML cells","volume":"532","author":"You","year":"2022","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.leukres.2024.107568_bib51","doi-asserted-by":"crossref","DOI":"10.4081\/oncol.2021.514","article-title":"Metformin - its anti-cancer effects in hematologic malignancies","volume":"15","author":"Podhorecka","year":"2021","journal-title":"Oncol. Rev."},{"issue":"22","key":"10.1016\/j.leukres.2024.107568_bib52","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.4161\/cc.26461","article-title":"Direct inhibition of hexokinase activity by metformin at least partially impairs glucose metabolism and tumor growth in experimental breast cancer","volume":"12","author":"Marini","year":"2013","journal-title":"Cell Cycle"},{"issue":"4","key":"10.1016\/j.leukres.2024.107568_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.currproblcancer.2023.100972","article-title":"Repurposing metformin in hematologic tumor: state of art","volume":"47","author":"Hu","year":"2023","journal-title":"Curr. Probl. Cancer"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212624001346?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212624001346?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T12:53:19Z","timestamp":1726231999000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212624001346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":53,"alternative-id":["S0145212624001346"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2024.107568","relation":{},"ISSN":["0145-2126"],"issn-type":[{"type":"print","value":"0145-2126"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolution of transcriptomic profiles in relapsed inv(16) acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2024.107568","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107568"}}